Baudax Bio, Inc. (BXRX) NASDAQ
0.02
+0.0015(+7.39%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Baudax Bio, Inc.
Address
490 Lapp Road
Malvern, PA 19355
United States of America (the)
Phone
484 395 2440
Website
Sector
Healthcare
Industry
Biotechnology
Employees
9
First IPO Date
November 14, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Geraldine A. Henwood | President, Chief Executive Officer & Director | 633,250 | 1952 |
| Chan Kim Yong | Chief Scientific Officer & Director | 0 | 1974 |
| Mike Choi | Vice President of Financial Planning & Analysis | 0 | N/A |
| Natalie McAndrew | Consultant & Principle Accounting Officer | 0 | 1971 |
Description
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
